CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, presented results from its preclinical studies investigating VT-1908 (the first topical formulation of mycophenolate) for treating uveitis at the recent Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics (1). Uveitis is the inflammation of a part of the eye, and is implicated in 30,000 new cases of legal blindness annually, in the United States

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage healthcare holding company, presented results from its preclinical studies investigating VT-1908 (the first topical formulation of mycophenolate) for treating uveitis at the recent Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics (1). Uveitis is the inflammation of a part of the eye, and is implicated in 30,000 new cases of legal blindness annually, in the United States